Dicerna Pharmaceuticals, Inc., a Novo Nordisk Company

Clinical trials sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk Company, explained in plain language.

Now part of Novo Nordisk A/S NVO NYSE

A biopharmaceutical company developing RNAi-based therapies, now part of Novo Nordisk.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 2 Completed 3 Terminated 1

Promising liver drug trial halted early: what it means for patients

Disease control Stopped early

This study tested a new drug called belcesiran in people with a genetic condition called alpha-1 antitrypsin deficiency that causes liver damage. The goal was to see if the drug is safe and can lower harmful protein levels in the liver. The trial was stopped early, so results are…

Phase 2 • Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company • Aim: Disease control

Last updated Jun 27, 2026 12:04 UTC

Dicerna Pharmaceuticals, Inc., a Novo Nordisk Company

Promising liver drug trial halted early: what it means for patients